Aurobindo Pharma share price
You have to be logged in to add this to Watchlist.- ₹1,475.00(-0.91%)May 11, 2026 15:29:57 PM IST
- NSE
- BSE
- Vol : 966.63 K (NSE + BSE)Last 20 day avg : 1.52 M
Aurobindo Pharma is trading -0.91% lower at Rs 1,475.00 as compared to its last closing price. Aurobindo Pharma has been trading in the price range of 1,504.55 & 1,464.05. Aurobindo Pharma has given 25.72% in this year & 7.04% in the last 5 days. Aurobindo Pharma has TTM P/E ratio 19.70 as compared to the sector P/E of 24.80.There are 26 analysts who have initiated coverage on Aurobindo Pharma. There are 9 analysts who have given it a strong buy rating & 12 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 910.29 Crores in its last quarter.Listed peers of Aurobindo Pharma include Jagsonpal Pharmaceuticals (-4.08%), Themis Medicare (6.98%), Neuland Laboratories (-0.82%).The Mutual Fund holding in Aurobindo Pharma was at 17.79% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Aurobindo Pharma was at 15.24% in 31 Mar 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on May 11, 2026, 03:37 PM UTC
- BetaLow volatility0.62Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.25The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.27Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation2.52The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals | Moderately Bullish | 209.00 | -4.08 | 1,412.28 | 33.88 | 5.54 | 1.25 | 3.18 |
| Themis Medicare | Bullish | 104.80 | 6.98 | 970.36 | 31.81 | 2.35 | 0.49 | 4.62 |
| Neuland Laboratories | Bullish | 17,548.30 | -0.82 | 22,431.43 | 92.96 | 12.69 | 0.08 | 7.17 |
| Pfizer | Moderately Bullish | 4,886.85 | 1.58 | 22,407.69 | 36.12 | 5.46 | 0.69 | 1.60 |
| Unichem Laboratories | Moderately Bullish | 383.30 | -0.47 | 2,702.52 | 23.18 | 1.29 | - | 3.51 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-04-06 | Buy Back of Shares |
| 2026-02-09 | Quarterly Results |
| 2025-11-05 | Quarterly Results |
| 2025-08-04 | Quarterly Results & Interim Dividend |
| 2025-05-26 | Audited Results |
- IndustryMajor Drugs
- ISININE406A01037
- BSE Code524804
- NSE CodeAUROPHARMA
Aurobindo Pharma is trading at 1475.00 as on Mon May 11 2026 09:59:57. This is -0.91% lower as compared to its previous closing price of 1488.50.
The market capitalization of Aurobindo Pharma is 85668.24 Cr as on Mon May 11 2026 09:59:57.
The average broker rating on Aurobindo Pharma is Buy. The breakup of analyst rating is given below -
- 9 analysts have given a strong buy rating
- 12 analysts have given a buy rating
- 1 analysts have given a hold rating
- 3 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Aurobindo Pharma is 1514.00 whereas the 52 wk low is 1017.00
Aurobindo Pharma can be analyzed on the following key metrics -
- TTM P/E: 19.70
- Sector P/E: 24.80
- Dividend Yield: 0.27%
- D/E ratio: -
Aurobindo Pharma reported a net profit of 3485.89 Cr in 2025.
The Mutual Fund Shareholding was 17.79% at the end of 31 Mar 2026.
EQUITY QUICK LINKS
Aurobindo Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.